Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q4 2025 Earnings Presentation
39 slides from Genedx's earnings presentation, Feb 23, 2026
Slide 1: GeneDx Q4 Earnings Presentation
GeneDx Nasdaq: WGS Q4 Earnings Presentation February 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market
Slide 3: Q4 and Full Year 2025 Results
Q4 and Full Year 2025 Results Metric Fourth Quarter 2025 Full Year 2025 Revenue1 $121.0 million $427.5 million (previous guidance was $425 to $428 million) 32% 54% Growth in exome and genome revenue (42% excluding a 2024 one-time benefit) (58% excluding a 2024 one-time benefit) (previous guidance wa
Slide 4: Full Year 2026 Guidance
Full Year 2026 Guidance Metric FY 2026 Guidance Revenue $540 to $555 million Growth in exome and genome revenue 33% to 35% Growth in exome and genome volume 33% to 35% Market contribution to growth: Foundational 25% - 27% Expansion 7% - 8% Future 1% Adjusted gross margin1 At least 70% Adjusted net i
Slide 5: Volume ramp continues
Volume ramp continues Exome and Genome Volume 140,000 Guide: 128k to 131k 120,000 Exome and genome test FY '22 - '25 CAGR 47% 97,271 result volume year-over-year: 100,000 80,000 74,547 • Full Year 2025: up 30.5% 60,000 49,439 • Q4 2025 YoY: up 34.3% to 27,761 40,000 30,560 20,000 • FY '26 Guidance:
Slide 6: Exome and genome revenue ramp continues
Exome and genome revenue ramp continues Exome and Genome Revenue (in $M) $600 $540-555 Exome and genome revenue Exome/genome year-over year: FY '22 - '25 $500 CAGR 61% $428 • Full Year 2025: up 54% (58% $400 excluding a 2024 one-time $302 benefit) $300 $486 $194 • Q4 2025 YoY: up 32% (42% $171 $360
Slide 7: Appendix
Appendix 7 Confidential & Proprietary. Do Not Distribute.
Slide 8: Empowering everyone to live their healthiest life through genomics
Empowering everyone to live their healthiest life through genomics 8
Slide 9: GeneDx is the global leader in rare disease diagnosis
GeneDx is the global leader in rare disease diagnosis The #1 genetic test GeneDx InfinityTM Experience & Technology Preferred by 80% of geneticists The largest and most diverse Diagnosing more rare disease and granted FDA Breakthrough rare disease dataset to deliver patients than anyone else and Dev
Slide 10: Supercharging growth to serve more patients globally
Supercharging growth to serve more patients globally Number of Exomes & Genomes 2026+ Expanding commercial team and entering new markets 1 Million Added 30% more tests to Infinity in 2025 than in the prior 24 years combined 750K 2025 AAP guidelines opened general pediatrics 500K 2017 Launched genome
Slide 11: An accurate genetic diagnosis is key to transforming healthcare
An accurate genetic diagnosis is key to transforming healthcare Enabling precision Providing an early Fueling genomic and accurate drug medicine genetic diagnosis discovery 11
Slide 12: Delivering the future of precision medicine via the network effect
Delivering the future of precision medicine via the network effect Patients Biopharma Delivering faster, more accurate diagnosis Accelerating drug discovery, enabling with personalized treatments based on clinical trials, and unlocking biomarkers for biology, leading to better outcomes targeted ther
Slide 13: Trusted by the nation's leading health systems
Trusted by the nation’s leading health systems 13
Slide 14: GeneDx Infinity is the largest and most diverse rare disease dataset
GeneDx InfinityTM is the largest and most diverse rare disease dataset ~1M >2.5M The most accurate exomes & genetic diagnosis genomes tests 2x the answers compared to public datasets >8M >8M Greatest scale advantage health phenotypic datapoints Fastest diagnosis and records most efficient operations
Slide 15: Our AI strategy accelerates the flywheel effect of our data
Higher diagnostic yields and more Additional Our AI strategy accelerates answers patients tested the flywheel effect of our data ELS OD M E M G A A U C The compounding power of the data G H IN AN from each new patient informs more E LARGE L LEA diagnoses and extends our lead RNING Proprietary AI mod
Slide 16: This large and ever-growing opportunity is ours to win
This large and ever-growing opportunity is ours to win Upside Opportunities International, Biopharma/Data, Precision Medicine Adult $20B Adult Neurologists, Adult Cardiologists, and Other Specialists Pediatrics & Rare Pediatric Specialists, Pediatricians, $25B NICU, Prenatal, and gNBS 16
Slide 17: On average, an accurate diagnosis takes 5 years
On average, an accurate diagnosis takes 5 years The economic burden of rare diseases in the U.S. is over $1 trillion annually Referral to a No diagnosis Visit primary care specialist physician Genetic testing (CMA) GeneDx provides First answers in symptom Online Another months research specialist Or
Slide 18: Payor coverage for exome and genome sequencing is expanding
Payor coverage for exome and genome sequencing is expanding 〉 GeneDx is contracted with 80% of covered lives, including all large national commercial payers 〉 Medicaid and commercial insurance coverage continues to grow for exome and genome o 38 states cover exome or genome testing o 17 states cover
Slide 19: Medicaid programs across the country are expanding access
Medicaid programs across the country are expanding access Current Medicaid Coverage Landscape Exome or Genome Sequencing Rapid Genome Sequencing Both No Coverage New or Enhanced Coverage 19 1. GeneDx Internal Data, data on file 2026
Slide 20: Our north star is to diagnose as many people as fast as possible
Our north star is to diagnose as many people as fast as possible 20
Slide 21: Our stacked, compounding growth strategy unlocks new opportunities
Our stacked, compounding growth strategy unlocks new opportunities Three layers, multiple building blocks to sustained high growth with disciplined expansion plan Future • gNBS Markets • New Channels (Developing) • BioPharma & Data Expansion • General Pediatricians (H2 2026) • NICU (since 2024) Mark
Slide 22: Large growth opportunities ahead to deepen penetration and expand our footprint
Large growth opportunities ahead to deepen penetration and expand our footprint Clinician Penetration by Market Patient Penetration by Market 100% 100% 90% 90% 80% 80% 70% 70% 60% 60% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Geneticsits Pediatric Geneticists Prenatal NICU Adult General Genetics
Slide 23: Entering new markets to deliver answers at the earliest moment possible
Entering new markets to deliver answers at the earliest moment possible Standard of care: years of disease progression Prenatal NICU Pediatrician Pediatric Geneticist Adult Specialist Specialist 23
Slide 24: Geneticists remain key customers and prefer GeneDx
Foundational Market Geneticists remain key customers and prefer GeneDx Geneticist recommendations reinforce our leadership in new markets Leading position: 80% market share driven by superior accuracy, broad access, and cutting-edge discovery Continued growth: Largest contributor to revenue today wi
Slide 25: Pediatric specialists drove a majority of 2025 growth
Foundational Market Pediatric specialists drove a majority of 2025 growth and have strong momentum entering 2026 Increased ordering and new customer activation driving expansion Significant share: Over 30% of pediatric neurologists now order from us with continued growth ahead Strong awareness: Grea
Slide 26: Pediatricians are becoming the new front line of genomic medicine
Expansion Pediatricians are becoming the new front line of Market genomic medicine First mover to an untapped market with the #1 genetic test in hand Massive market: 600K patients diagnosed with DD/ID by 25K pediatricians annually Trusted partner & clear leader: Leading product, wraparound services,
Slide 27: The NICU is an untapped opportunity for early intervention
Expansion Market The NICU is an untapped opportunity for early intervention and improved outcomes Taking a protocol-driven approach to benefit more patients and lower healthcare costs Large unmet need: Up to 60% NICU patients could benefit from rWGS per SeqFirst (~235k patients) but less than 5% of
Slide 28: GenomeDx Prenatal extends our diagnostic capabilities into prenatal care
Expansion GenomeDx Prenatal extends our industry-leading Market diagnostic capabilities into prenatal care Setting a new standard for prenatal genomic diagnoses Large unmet need: For patients with structural anomalies on prenatal ultrasound, impacting up to 4% of pregnancies Extensive prenatal exper
Slide 29: Adult specialists will unlock future growth and impact
Expansion Market Adult specialists will unlock future growth and impact Putting commercial focus behind the organic growth in adult exome and genome testing New market: Expanding to neurologists in 2026 with a focus on clinicians already ordering genetic testing Green space: Strong demand and reimbu
Slide 30: Global reach with decentralized testing powered by GeneDx Infinity
Expansion Global reach with decentralized testing powered by Market centralized intelligence from GeneDx Infinity Cloud-native platform enables remote interpretation while complying with local regulations Expanded international footprint with sales reps in key geographies Providing leading interpret
Slide 31: Transforming healthcare from diagnostic odyssey to day one action with gNBS
Future Transforming healthcare from diagnostic odyssey to Market day one action with gNBS GeneDx has the evidence, experience, and operational capabilities to lead global adoption Evidence Experience Capabilities Data from the GUARDIAN study: • Sequenced >22,000 newborns • Flexible services – from e
Slide 32: Pioneering new channels and partnerships for precision genomic medicine
Future Pioneering new channels and partnerships to deliver Market on the promise of precision genomic medicine 32
Slide 33: Deploying the most comprehensive, longitudinal dataset for rare disease
Future Deploying the most comprehensive, longitudinal Market dataset for rare disease ever assembled Genetic data Claims Electronic Prescription health records Patient Imaging demographics Unlocking faster HEOR, biopharma innovation, and AI-driven discovery 33
Slide 34: Transforming every stage of drug development
Transforming every stage of drug development Research & Clinical Launch & Market Authorization Development Trials Post-Marketing & Access Target Validation Patient Matching Diverse Commercialization & Modeling & Recruitment Longitudinal Data 34
Slide 35: Turning insight into biopharma impact
Turning insight into biopharma impact 35
Slide 36: Proven leadership driving high-growth and operational excellence at scale
Proven leadership driving high-growth and operational excellence at scale Katherine Stueland Kevin Feeley Bryan Dechairo Melanie Duquette Lisa Gurry Chief Executive Officer Chief Financial Officer Chief Operating Officer Chief Growth Officer Chief Business Officer Heidi Chen Linda Genen Jami Biliboa
Slide 37: A rare opportunity to transform healthcare fueled by unmatched data and momentum
A rare opportunity to transform healthcare fueled by unmatched data and momentum Massive TAM and expanding Emerging guidelines and serviceable market improving payer landscape Leadership position Scale advantage Differentiated technology Proven management team 37
Slide 38: GeneDx enables a future that is predictive, preventative, and ultimately curative
GeneDx enables a future that is predictive, preventative, and ultimately curative. That future always begins with a single answer. And that answer changes everything. 38
Slide 39: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures Adjusted gross profit, adjusted gross margin, and adjusted net income (in $ thousands) Three months ended December 31, Year ended December 31, 2025 2024 2025 2024 GeneDx Other1 Total GeneDx Other1 Total GeneDx Other1 Total GeneDx Other1 Total Revenue $11